Table 2.
Epidemiological, clinical and laboratory findings in 34 β-thalassemia major (β-TM) patients at final evaluation, classified in three groups based on OGTT: A with NGT; B with IGT and IFG plus IGT and C with β-TM-RD.
| Variables | Group A (NGT) (n.12) |
Group B (IGT and IFG+ IGT) (n.16) |
Group C (β-TM-RD) (n.6) |
|---|---|---|---|
| Chronological age (yrs) | 34.6 ± 5.3 | 42.0 ± 3.8 | 38.6 ± 4.7 |
| Gender (Males/Females) | 3/9 | 10/6 | 2/4 |
|
BMI (Kg/m2)
Mean and SD Range |
22.1 ± 2.8 18 -23.8 |
22.8 ± 2.3 19.9-27.7 |
26.2 ± 7.1 20.5- 40.1 |
|
Family history of diabetes:
Type 1 Type 2 |
1 1 |
4 3 |
- 1 |
|
Serum ferritin (ng/mL) - Mean and SD < 500 ng/mL (n. and %) |
862.8 ± 668.7 5 (41.6%) |
661.8 ± 484.9 5 (31.2%) |
1730.0 ± 1326.5 1 (16.6%) |
|
LIC (mg/g dry weight)
Cardiac T2* (msec) |
1.87 ± 0.93 (11 pts) 35.0 ± 14.5 (11 pts) |
2.10 ± 1.8 (13 pts) 25.8 ± 9.6 (12 pts) |
7.0 ± 5.5 (4 pts) 20.9 ± 6.1 (3 pts) |
|
Chelation therapy:
Desferrioxamine (DFO) Deferiprone (DFP) Deferasirox (DFX) DFO plus DFP |
7 1 2 2 |
13 2 1 - |
2 2 - 2 |
|
ALT (U/L) -
Mean and SD |
27.3 ± 7.7 | 43.8 ± 31.3 | 58.6 ± 31.5 |
|
HCV-ab positive ( %) HCV –RNA positive (%) |
91.6 41.6 |
100 62.5 |
100 66.6 |
|
IGF-1 (ng/mL) -
Mean and SD Range Median Quartile: Q1-3 |
126.2 ± 34.1
50.7- 197.3 123.6 109.7-143.8 |
56.0 ± 38.3
27.3 - 150.5 40 30.2-71.3 |
31.2 ± 6.0
19.1-37 31.9 29.4 -37.0 |
| Plasma glucose (mg/dL) at baseline - Mean and SD | 92.8 ± 4.0 | 98.1 ± 9.3 | 138.8 ± 26.9 |
| Plasma glucose (mg/dL) after 1 h OGTT- Mean and SD | 128.1 ± 18.7 | 168.4 ± 36.0 | 254.0 ± 40.4 |
| Plasma glucose (mg/dL) after 2 h OGTT- Mean and SD | 122.5 ± 12.2 | 161.1 ± 16.5 | 251.5 ± 35.6 |
| Fasting insulin (μU/mL) | 5.7 ± 2.5 | 5.6 ± 2.8 | 9.6 ± 4.0 |
| Insulin peak (μU/mL) during OGTT- Mean and SD | 49.2 ± 18.5 | 59.1 ± 30.6 | 43.0 ± 30.6 |
| Delayed insulin peak (90'-120' minutes) after OGTT | 33.3 % | 81.2% | 83.3% |
| Plasma insulin (μU/mL) after 2 h OGTT - Mean and SD | 35.0 ± 19.6 | 56.3 ± 33.7 | 42.0 ± 31.2 |